Pharmacia & Upjohn
MITABAN庐 Liquid Concentrate
MATERIAL SAFETY DATA SHEET
Agent ID# 29294
EFFECTS OF OVEREXPOSURE: Ingestion may cause
1. CHEMICAL PRODUCT AND hyperglycemia, hypothermia and/or central nervous system
COMPANY IDENTIFICATION depression. Inhalation may cause central nervous system
depression, nasal discharge and/or dyspnea. Prolonged
skin contact may lead to irritation, dermatitis and/or
allergic reactions. Contact with haircoats of dogs within
COMMON NAME: MITABAN庐 Liquid Concentrate
several days post-treatment may lead to skin reactions,
SYNONYMS: 402839 鈥? EDP Number
especially in children. Skin absorption may result in
MOLECULAR FORMULA: Mixture
systemic effects. Eye contact may lead to conjunctival
CHEMICAL FAMILY: Mixture
irritation, iritis and corneal opacity, and can be corrosive.
USE: Veterinary product indicated for the treatment of
generalized demodicosis (Demodex canis) in dogs. Not for
human use. 4. FIRST AID MEASURES
MANUFACTURER/SUPPLIER:
PHARMACIA & UPJOHN CO., A SUBSIDIARY OF
EYES: Rinse immediately with water for 15 minutes; call a
PHARMACIA CORP.
physician immediately.
7171 PORTAGE RD
SKIN: Wash with soap and water; remove contaminated
KALAMAZOO, MI 49001-0199
clothing and shoes. Consult a physician.
TELEPHONE NUMBERS:
INHALATION: Remove person from further exposure.
(616) 833-5122 - (24 Hours)
INGESTION: Do not induce vomiting. Call a physician
(616) 833-7555 - (8:00 AM - 4:30 PM, EST)
immediately.
NOTES TO PHYSICIAN: MITABAN is a mixture of
2. COMPOSITION/INFORMATION amitraz, propylene oxide and xylene. The time of onset
ON INGREDIENTS and duration of symptoms from accidental overexposure
has not been determined. Sedation has been seen in dogs
from 2 to 6 hours post-treatment with dissipation occurring
INGREDIENT 1
in 24 to 72 hours. MITABAN and its components are
COMMON NAME: Xylene (o-, m-, p- isomers)
known to be absorbed through the skin. Chronic
% BY WEIGHT: 74.5 %
overexposure may lead to altered homeostasis and target
CAS NUMBER: 1330-20-7
organ damage; including central nervous system
EXPOSURE LIMIT(S): OHSA PEL-TWA: 100 PPM
depression and liver damage due to xylene. There is no
OSHA PEL-STEL: 150 PPM
known antidote for MITABAN or its components. The
ACGIH TLV-TWA: 100 PPM
product is packaged in 10.6-mL vials. Medical
ACGIH TLV-STEL: 150 PPM
management for ingested MITABAN is gastric lavage.
Induction of vomiting may be contraindicated because the
INGREDIENT 2
product contains xylene and emesis risks entry of stomach
COMMON NAME: Amitraz
contents into the respiratory tract. Subsequent treatment is
CHEMICAL NAME: Methanimidamide, N鈥? -(2,4-
symptomatic and supportive. There is experimental
dimethylphenyl)-N-[[(2,4-dimethylphenyl)imino]methyl]-
evidence that systemic effects resulting from ingestion are
N-m-ethyl-
not ameliorated by absorption retardants, specific antidote
% BY WEIGHT: 21% to 24%
therapy, induction of diuresis or modification of urine pH.
CAS NUMBER: 33089-61-1
In most circumstances, the chemical should be removed
EXPOSURE LIMIT(S): Not established.
from the stomach if the amount is large (several ounces).
Removal is indicated if the chemical is a carrier for a more
INGREDIENT 3
toxic substance such as a pesticide. If gastric lavage is
COMMON NAME: Propylene Oxide
carried out, it should use the largest practical nasogastric
% BY WEIGHT: 1 %
or orogastric tube, with a cuffed endotracheal tube in
CAS NUMBER: 75-56-9
place. Follow the above with an activated charcoal slurry:
EXPOSURE LIMIT(S): OSHA PEL-TWA: 20 PPM
adult dose is 50 to 100 g; pediatric 30 to 50 g. Follow the
OSHA PEL-TWA (Transitional limit): 100 PPM
above by administering a cathartic such as magnesium
ACGIH TLV-TWA: 20 PPM
sulfate (adults: 30 g or 300 cc of 10% solution; pediatric:
250 mg/kg) or magnesium citrate. Cathartics alone may
EXPOSURE LIMIT(S) FOR THE MATERIAL: Not
suffice for small ingestions. General supportive measures
established.
should be used, as indicated.
3. HAZARDS IDENTIFICATION
5. FIRE FIGHTING MEASURES
PRIMARY ROUTE(S) OF EXPOSURE: Skin contact,
FLASH POINT: 13潞 C (55潞 F) (flammable liquid)
eye contact, ingestion, and inhalation.
1
Pharmacia & Upjohn
MITABAN庐 Liquid Concentrate
MATERIAL SAFETY DATA SHEET
Agent ID# 29294
LOWER EXPLOSION LIMIT (LEL): Not applicable. MOLECULAR WEIGHT: Mixture.
UPPER EXPLOSION LIMIT (UEL): Not applicable. ODOR: Aromatic smell of xylene.
EXTINGUISHING MEDIA: Foam, carbon dioxide or dry SOLUBILITY IN WATER: Insoluble.
chemical.
FIRE FIGHTING PROCEDURES: Wear self-contained
10. STABILITY AND REACTIVITY
breathing apparatus and full-body protective equipment.
UNUSUAL FIRE OR EXPLOSION HAZARDS: Severe
in the form of vapor when exposed to heat or flame. STABILITY: Conditions contributing to instability: direct
HAZARDOUS COMBUSTION PRODUCTS: Carbon flame.
monoxide. Carbon dioxide. Nitrogen oxides. PHYSICAL CONDITIONS TO AVOID: None.
INCOMPATIBILITY WITH OTHER MATERIALS:
Oxidizing agents.
6. ACCIDENTAL RELEASE MEASURES
HAZARDOUS DECOMPOSITION PRODUCTS: Vapors
may be toxic.
HAZARDOUS POLYMERIZATION: Does not occur.
STEPS TO BE TAKEN IN CASE MATERIAL IS
RELEASED OR SPILLED: Absorb large spills with
appropriate absorbents. Remove container to safe place
11. TOXICOLOGICAL INFORMATION
where leakage can be stopped. Shut off all sources of
potential ignition. Extinguish all flames.
ACUTE STUDIES:
SKIN LD50 (MOUSE): 71 g/kg
7. HANDLING AND STORAGE
INHALATION LC50 (RAT): >2.3 mg/L
ORAL LD50 (MOUSE): 1,500 mg/kg
OTHER STUDIES:
PRECAUTIONS FOR HANDLING AND STORING:
The handling precautions specified are recommended CARCINOGENICITY: MITABAN is not listed as a
when handling and application of formulated products. carcinogen by IARC, NTP or OSHA. Amitraz, the active
Read the product label for precautionary statements and ingredient in MITABAN, has been designated as a group
directions for use. Keep out of reach of children. Harmful C carcinogen by EPA on the basis of induction of liver
or fatal if swallowed. Do not store near food or feed. This tumors in female mice at doses exceeding the MTD.
product is toxic to fish. Keep out of lakes, ponds or Possibly carcinogenic for humans based on limited animal
streams. Causes eye and skin irritation. Do not get in eyes, evidence in the absence of human data.
on skin or on clothing. Wear rubber gloves and protective
clothing when handling. Avoid breathing vapors or spray
12. DISPOSAL CONSIDERATIONS
mist. Do not contaminate water by cleaning of equipment
or disposal of wastes. Wash thoroughly after handling.
Keep container closed. Do not reuse container. WASTE DISPOSAL METHOD: Dispose of by incinera-
tion in accordance with applicable international, national,
state and/or local waste disposal regulations.
8. EXPOSURE CONTROLS/
PERSONAL PROTECTION
13. SHIPPING REGULATIONS
RESPIRATORY PROTECTION: Recommended during
prolonged or repeated use during the work day. PROPER SHIPPING NAME: Consumer commodity.
VENTILATION: Local exhaust. HAZARD CLASS: ORM-D.
PROTECTIVE GLOVES: Resistant to aromatic solvents
(i.e., polyethene).
14. OTHER INFORMATION
EYE PROTECTION: Safety glasses with side shields.
OTHER PROTECTIVE EQUIPMENT: Protective
covering for exposed areas of skin. Wear clean clothing
REVIEWED BY: Environment & Safety.
each day and launder before reusing. Use non-sparking
DISCLAIMER: The information contained in the MSDS is
tools and equipment.
believed to be correct as of its date of issuance. BY
MAKING THE MSDS AVAILABLE, PHARMACIA &
9. PHYSICAL AND CHEMICAL UPJOHN CO. DOES NOT MAKE ANY EXPRESS OR
PROPERTIES IMPLIED WARRANTY (INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS
FOR A PARTICULAR PURPOSE) REGARDING THE
APPEARANCE/PHYSICAL STATE: Pale, amber-brown
MSDS, ITS ACCURACY OR THE PRODUCT TO
liquid.
WHICH IT RELATES. Anyone using this information
MELTING POINT: Not applicable.
2
Pharmacia & Upjohn
MITABAN庐 Liquid Concentrate
MATERIAL SAFETY DATA SHEET
Agent ID# 29294
agrees that Pharmacia & Upjohn shall not be held liable
(based on its negligence or otherwise) for any personal
injury or other damage relating to, or arising from such
use, including direct, incidental, or consequential damage
and such user agrees to indemnify Pharmacia & Upjohn
for any claims arising out of its use.
15. LABELING
This drug is subject to FDA labeling requirements; there-
fore, it is exempt from the labeling requirements of the
OSHA Hazard Communication Standard.
NDC 0009-3118-01
July 31, 2001
3
|